vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Yatsen Holding Ltd (YSG). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $164.2M, roughly 1.2× Yatsen Holding Ltd). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 24.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Yatsen Holding Ltd is a leading China-based beauty and personal care group. It develops and sells cosmetics, skincare products and fragrances under brands including Perfect Diary, Little Ondine and Abby's Choice, with core markets in mainland China, Southeast Asia, targeting Gen Z and young adult consumers.
AXSM vs YSG — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $164.2M |
| Net Profit | — | $-776.5K |
| Gross Margin | — | 77.8% |
| Operating Margin | -33.1% | -34.0% |
| Net Margin | — | -0.5% |
| Revenue YoY | 57.4% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $164.2M | ||
| Q3 25 | $171.0M | $95.1M | ||
| Q2 25 | $150.0M | $110.9M | ||
| Q1 25 | $121.5M | $106.6M | ||
| Q4 24 | $118.8M | $147.0M | ||
| Q3 24 | $104.8M | $102.3M | ||
| Q2 24 | $87.2M | $118.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $-776.5K | ||
| Q3 25 | $-47.2M | $-17.0M | ||
| Q2 25 | $-48.0M | $-11.9M | ||
| Q1 25 | $-59.4M | $-17.2M | ||
| Q4 24 | $-74.9M | $-67.7M | ||
| Q3 24 | $-64.6M | $-28.2M | ||
| Q2 24 | $-79.3M | $-14.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 77.8% | ||
| Q3 25 | — | 75.9% | ||
| Q2 25 | — | 76.7% | ||
| Q1 25 | — | 77.7% | ||
| Q4 24 | — | 73.7% | ||
| Q3 24 | — | 71.4% | ||
| Q2 24 | — | 74.7% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | -34.0% | ||
| Q3 25 | -27.0% | -20.9% | ||
| Q2 25 | -24.5% | -17.0% | ||
| Q1 25 | -46.9% | -20.4% | ||
| Q4 24 | -61.1% | -50.3% | ||
| Q3 24 | -59.8% | -32.2% | ||
| Q2 24 | -89.5% | -15.7% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | -0.5% | ||
| Q3 25 | -27.6% | -17.9% | ||
| Q2 25 | -32.0% | -10.8% | ||
| Q1 25 | -48.9% | -16.1% | ||
| Q4 24 | -63.1% | -46.1% | ||
| Q3 24 | -61.7% | -27.6% | ||
| Q2 24 | -91.0% | -12.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $109.4M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $428.9M |
| Total Assets | $713.6M | $550.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $109.4M | ||
| Q3 25 | $325.3M | $97.0M | ||
| Q2 25 | $303.0M | $133.1M | ||
| Q1 25 | $300.9M | $92.3M | ||
| Q4 24 | $315.4M | $112.0M | ||
| Q3 24 | $327.3M | $71.7M | ||
| Q2 24 | $315.7M | $109.6M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $428.9M | ||
| Q3 25 | $73.7M | $423.1M | ||
| Q2 25 | $73.1M | $431.5M | ||
| Q1 25 | $53.2M | $422.2M | ||
| Q4 24 | $57.0M | $418.1M | ||
| Q3 24 | $92.9M | $516.0M | ||
| Q2 24 | $102.9M | $519.4M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $550.1M | ||
| Q3 25 | $669.3M | $564.8M | ||
| Q2 25 | $639.8M | $564.4M | ||
| Q1 25 | $596.7M | $534.3M | ||
| Q4 24 | $568.5M | $544.0M | ||
| Q3 24 | $561.5M | $635.6M | ||
| Q2 24 | $548.2M | $635.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
YSG
Segment breakdown not available.
